neuroscience

AbbVie Completes Acquisition of Cerevel Therapeutics

AbbVie has completed its acquisition of Cerevel Therapeutics. According to AbbVie, Cerevel's pipeline is highly complementary to its own existing neuroscience portfolio. The takeover was announced in December 2023.

AbbVie to Acquire Cerevel Therapeutics for $8.7 Billion

In a move to complement its neuroscience portfolio, US drugmaker AbbVie has agreed to acquire Cerevel Therapeutics, which has a pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson's disease (PD), and mood disorders.

Shire Mulls Separation of Neurosciences

Merck Takes Antibody License from Teijin

Bioelectronic Medicines: A New Type of Personalization

Lilly CEO Lechleiter to Retire in December

Novartis Splits Pharmaceutical Division

Novartis Buys Rights to Multiple Sclerosis Drug from GlaxoSmithKline

New J&J Anti-depressant Related to "Special K" Party Drug

AstraZeneca Tries New Tack in Brain Research